Laboratory of Experimental Trauma Surgery, Justus-Liebig University, Giessen, Germany.
Int J Exp Pathol. 2013 Dec;94(6):387-98. doi: 10.1111/iep.12038. Epub 2013 Sep 2.
Osteoporosis is one of the deleterious side effects of long-term glucocorticoid therapy. Since the condition is particularly aggressive in postmenopausal women who are on steroid therapy, in this study we have attempted to analyse the combined effect of glucocorticoid (dexamethasone) treatment and cessation of oestrogen on rat bone. The dual aim was to generate osteoporotic bone status in a short time scale and to characterise the combination of glucocorticoid-postmenopausal osteoporotic conditions. Sprague Dawley rats (N = 42) were grouped randomly into three groups: untreated control, sham-operated and ovariectomized-steroid (OVX-Steroid) rats. Control animals were euthanized with no treatment [Month 0 (M0)], while sham and OVX-Steroid rats were monitored up to 1 month (M1) and 3 months (M3) post laparotomy/post OVX-Steroid treatment. Histology, dual-energy X-ray absorptiometry (DXA), micro-computed tomography (micro-CT), and biomechanical and mRNA expression analysis of collagenous, non-collagenous matrix proteins and osteoclast markers were examined. The study indicated enhanced osteoclastogenesis and significantly lower bone mineral density (BMD) in the OVX-Steroid rats with Z-scores below -2.5, reduced torsional strength, reduced bone volume (BV/TV%), significantly enhanced trabecular separation (Tb.S), and less trabecular number (Tb.N) compared with sham rats. Osteoclast markers, cathepsin K and MMP 9 were upregulated along with Col1α1 and biglycan with no significant expression variation in fibronectin, MMP 14, LRP-5, Car II and TNC. These results show higher bone turnover with enhanced bone resorption accompanied with reduced torsional strength in OVX-Steroid rats; and these changes were attained within a short timeframe. This could be a useful model which mimics human postmenopausal osteoporosis that is associated with steroid therapy and could prove of value both in disease diagnosis and for testing generating and testing biological agents which could be used in treatment.
骨质疏松症是长期糖皮质激素治疗的有害副作用之一。由于在接受类固醇治疗的绝经后妇女中,这种情况特别严重,因此在这项研究中,我们试图分析糖皮质激素(地塞米松)治疗和雌激素停止对大鼠骨骼的综合影响。双重目的是在短时间内产生骨质疏松症骨骼状态,并描述糖皮质激素-绝经后骨质疏松症的联合状况。随机将 Sprague Dawley 大鼠(N = 42)分为三组:未处理对照组、假手术组和卵巢切除-类固醇(OVX-类固醇)组。对照组动物未经治疗即被安乐死[第 0 个月(M0)],而假手术和 OVX-类固醇组动物在剖腹术/OVX-类固醇治疗后 1 个月(M1)和 3 个月(M3)进行监测。进行组织学、双能 X 射线吸收法(DXA)、微计算机断层扫描(micro-CT)以及胶原、非胶原基质蛋白和破骨细胞标志物的生物力学和 mRNA 表达分析。研究表明,OVX-类固醇大鼠的破骨细胞生成增强,骨矿物质密度(BMD)明显降低(Z 评分低于-2.5),扭转强度降低,骨体积(BV/TV%)降低,骨小梁分离(Tb.S)显著增加,骨小梁数量(Tb.N)减少与假手术大鼠相比。破骨细胞标志物组织蛋白酶 K 和 MMP 9 上调,同时 Col1α1 和 biglycan 上调,而纤连蛋白、MMP 14、LRP-5、Car II 和 TNC 的表达无明显变化。这些结果表明,OVX-类固醇大鼠的骨转换率更高,骨吸收增强,扭转强度降低;这些变化在短时间内发生。这可能是一种有用的模型,可模拟与类固醇治疗相关的人类绝经后骨质疏松症,并可能在疾病诊断和测试生成和测试可用于治疗的生物制剂方面具有价值。